Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine - PubMed (original) (raw)
Jian-San Zhang, Nan Su, Jian-Guo Xu, Nan Wang, Jiang-Ting Chen, Xin Chen, Yu-Xuan Liu, Hong Gao, Yu-Ping Jia, Yan Liu, Rui-Hua Sun, Xu Wang, Dong-Zheng Yu, Rong Hai, Qiang Gao, Ye Ning, Hong-Xia Wang, Ma-Chao Li, Biao Kan, Guan-Mu Dong, Qi An, Ying-Qun Wang, Jun Han, Chuan Qin, Wei-Dong Yin, Xiao-Ping Dongs
Affiliations
- PMID: 18018769
Clinical Trial
Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine
Jiang-Tao Lin et al. Antivir Ther. 2007.
Abstract
Background: Emergence of severe acute respiratory syndrome (SARS) from the winter of 2002 to the spring of 2003 has caused a serious threat to public health.
Methods: To evaluate the safety and immunogenicity of the inactivated SARS coronavirus (SARS-CoV) vaccine, 36 subjects received two doses of 16 SARS-CoV units (SU) or 32 SU inactivated SARS-CoV vaccine, or placebo control.
Results: On day 42, the seroconversion reached 100% for both vaccine groups. On day 56, 100% of participants in the group receiving 16 SU and 91.1% in the group receiving 32 SU had seroconverted. The geometric mean titre of neutralizing antibody peaked 2 weeks after the second vaccination, but decreased 4 weeks later.
Conclusion: The inactivated vaccine was safe and well tolerated and can elicit SARS-CoV-specific neutralizing antibodies.
Similar articles
- Immunogenicity of SARS inactivated vaccine in BALB/c mice.
Xiong S, Wang YF, Zhang MY, Liu XJ, Zhang CH, Liu SS, Qian CW, Li JX, Lu JH, Wan ZY, Zheng HY, Yan XG, Meng MJ, Fan JL. Xiong S, et al. Immunol Lett. 2004 Sep;95(2):139-43. doi: 10.1016/j.imlet.2004.06.014. Immunol Lett. 2004. PMID: 15388253 Free PMC article. - A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
Spruth M, Kistner O, Savidis-Dacho H, Hitter E, Crowe B, Gerencer M, Brühl P, Grillberger L, Reiter M, Tauer C, Mundt W, Barrett PN. Spruth M, et al. Vaccine. 2006 Jan 30;24(5):652-61. doi: 10.1016/j.vaccine.2005.08.055. Epub 2005 Aug 26. Vaccine. 2006. PMID: 16214268 Free PMC article. - Humoral immune responses in rabbits induced by an experimental inactivated severe acute respiratory syndrome coronavirus vaccine prepared from F69 strain.
Zhang CH, Guo ZM, Zheng HY, Lu JH, Wang YF, Yan XG, Zhao Y, DU XW, Zhang X, Fang L, Ling WH, Qi SY, Yu XB, Zhong NS. Zhang CH, et al. Chin Med J (Engl). 2004 Nov;117(11):1625-9. Chin Med J (Engl). 2004. PMID: 15569476 - Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.
Cavanagh D. Cavanagh D. Avian Pathol. 2003 Dec;32(6):567-82. doi: 10.1080/03079450310001621198. Avian Pathol. 2003. PMID: 14676007 Free PMC article. Review. - SARS Immunity and Vaccination.
Zhu M. Zhu M. Cell Mol Immunol. 2004 Jun;1(3):193-8. Cell Mol Immunol. 2004. PMID: 16219167 Review.
Cited by
- Nanotherapeutics for treating coronavirus diseases.
Gunathilake TMSU, Ching YC, Uyama H, Chuah CH. Gunathilake TMSU, et al. J Drug Deliv Sci Technol. 2021 Aug;64:102634. doi: 10.1016/j.jddst.2021.102634. Epub 2021 Jun 10. J Drug Deliv Sci Technol. 2021. PMID: 34127930 Free PMC article. Review. - Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.
Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. Tseng CT, et al. PLoS One. 2012;7(4):e35421. doi: 10.1371/journal.pone.0035421. Epub 2012 Apr 20. PLoS One. 2012. PMID: 22536382 Free PMC article. - Applying two behavioral theories to predict the willingness to receive COVID-19 vaccine booster in the elderly: A cross-sectional study.
Wang J, Li T, Ge J, Zhou M, Walker AN, Chen J, Zhang T, Zhang K, Gu S, You H. Wang J, et al. Res Social Adm Pharm. 2023 Mar;19(3):495-501. doi: 10.1016/j.sapharm.2022.10.011. Epub 2022 Nov 3. Res Social Adm Pharm. 2023. PMID: 36357271 Free PMC article. - Annexin A2 on lung epithelial cell surface is recognized by severe acute respiratory syndrome-associated coronavirus spike domain 2 antibodies.
Fang YT, Lin CF, Liao PC, Kuo YM, Wang S, Yeh TM, Shieh CC, Su IJ, Lei HY, Lin YS. Fang YT, et al. Mol Immunol. 2010 Feb;47(5):1000-9. doi: 10.1016/j.molimm.2009.11.019. Epub 2009 Dec 16. Mol Immunol. 2010. PMID: 20015551 Free PMC article. - COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics.
Amawi H, Abu Deiab GI, A Aljabali AA, Dua K, Tambuwala MM. Amawi H, et al. Ther Deliv. 2020 Apr;11(4):245-268. doi: 10.4155/tde-2020-0035. Epub 2020 May 12. Ther Deliv. 2020. PMID: 32397911 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous